Dishman Carbogen Amcis Limited is a global pharmaceutical contract development and manufacturing organization (CDMO) that specializes in the development and manufacturing of active pharmaceutical ingredients (APIs), intermediates, and specialized drug products. With over three decades of experience, the company has established itself as a trusted partner for pharmaceutical companies worldwide. The company operates through three key business segments: the Development Solutions segment, the Manufacturing Solutions segment, and the Commercial Solutions segment.
- Dishman Carbogen Amcis Limited reported Total Income for Q4 FY23 of ₹625.31 Crore up from ₹573.36 Crore year on year, a growth of 9%.
- Total Expenses for Q4 FY23 of ₹667.29 Crore up from ₹646.52 Crore year on year, a growth of 3.2%.
- Consolidated Net Loss of ₹70.72 Crore, widens from loss of ₹44.62 Crore in the same quarter of the previous year.
Most Popular
Cochin Shipyard Ltd (COCHINSHIP) Q4 FY22 Earnings Concall Transcript
Cochin Shipyard Limited (NSE:COCHINSHIP) Q4 FY22 Earnings Concall dated May. 26, 2022 Corporate Participants: Madhu S Nair -- Chairman & Managing Director Jose V J -- Director Finance Analysts: Vastupal Shah
All you need to know about Antony Waste Handling Cell in one article
Can you guess the name of the company that was listed during the IPO frenzy in 2020 and is the second largest player in the Indian municipal waste management industry?
Demystifying the Leading Non-Ferrous Recycling Company of India
“Hey, how is the market doing today?” “Oh!, its falling tremendously since morning” I am sure news like these might be a common topic of discussion for you nowadays. Interestingly,